المؤلفون: K. Yu. Mukhin, O. A. Pylaeva, M. Yu. Bobylova, L. Yu. Glukhova, N. V. Freydkova, К. Ю. Мухин, О. А. Пылаева, М. Ю. Бобылова, Л. Ю. Глухова, Н. В. Фрейдкова

المساهمون: The publication was prepared with the financial support of the Eisai Company., Публикация подготовлена при финансовой поддержке компании «Эйсай».

المصدر: Russian Journal of Child Neurology; Том 18, № 4 (2023); 8-25 ; Русский журнал детской неврологии; Том 18, № 4 (2023); 8-25 ; 2412-9178 ; 2073-8803

مصطلحات موضوعية: у взрослых, Lennox–Gastaut syndrome, new antiepileptic drug, rufinamide, effectiveness and tolerability, in children and adolescents, in adults, синдром Леннокса–Гасто, новый антиэпилептический препарат, руфинамид, эффективность и переносимость, у детей и подростков

وصف الملف: application/pdf

العلاقة: https://rjdn.abvpress.ru/jour/article/view/448/305Test; Белоусова Е.Д., Бурд С.Г., Ермоленко Н.А., Мухин К.Ю. Диагностика и возрастная эволюция синдрома Леннокса–Гасто. Ведение пациентов в разных возрастных периодах. Эпилепсия и пароксизмальные состояния 2022;14(3):276–93. DOI:10.17749/2077-8333/epi.par.con.2022.124; Мухин К.Ю., Петрухин А.С. Эпилептические синдромы. Клинико-электроэнцефалографическая диагностика и терапия. В кн.: Эпилептические синдромы. Диагностика и терапия (руководство для врачей). М.: Русский печатный двор, 2023. С. 146–323.; Мухин К.Ю., Пылаева О.А. Руфинамид (Иновелон) в лечении синдрома Леннокса–Гасто (обзор литературы и описание случая). Русский журнал детской неврологии 2015;10(4):47–54. DOI:10.17650/2073-8803-2015-10-4-47-54; Мухин К.Ю., Пылаева О.А., Бобылова М.Ю. и др. Эффективность и переносимость руфинамида в лечении эпилепсии (опыт Института детской неврологии и эпилепсии им. Святителя Луки). Русский журнал детской неврологии 2018;13(2):7–19. DOI:10.17650/2073-8803-2018-13-2-7-19; Мухин К.Ю., Пылаева О.Н. Руфинамид (Иновелон) в лечении синдрома Леннокса–Гасто (обзор литературы). Русский журнал детской неврологии 2018;13(2):20–33. DOI:10.17650/2073-8803-2018-13-2-20-33; Общая характеристика лекарственного препарата Иновелон® (руфинамид), таблетки, покрытые пленочной оболочкой. РУ ЛП-№(001228)-(РГ-RU). Единый реестр зарегистрированных лекарственных средств Евразийского экономического союза. Доступно по: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/DrugRegistrationDetails.aspxTest.; Пылаева О.А., Мухин К.Ю. Побочные эффекты антиэпилептической терапии: общие закономерности развития и принципы профилактики. В кн.: Эпилептические синдромы. Диагностика и терапия. Руководство для врачей. 5-е изд-е. М.: Русский печатный двор, 2023. С. 540–596.; Пылаева О.А., Мухин К.Ю., Петрухин А.С. Побочные эффекты антиэпилептической терапии. М.: Гранат, 2016. 236 с.; Эпилепсия. Атлас электроклинической диагностики и терапии. Том I. Под ред. К.Ю. Мухина, Л.Ю. Глуховой, А.А. Холина. М.: Русский печатный двор, 2023. 912 с.; Aldenkamp A., Besag F., Gobbi G. et al. Psychiatric and behavioural disorders in children with epilepsy (ILAE Task Force report): Adverse cognitive and behavioral effects of antiepileptic drugs in children. Epileptic Disord 2016;19(2):178–85. DOI:10.1684/epd.2016.0817; Borrelli S., El Tahry R. Therapeutic approach to Lennox–Gastaut syndrome: A systematic review. Acta Neurol Belg 2019;119(3):315–24.; Brigo F., Jones K., Eltze C., Matricardi S. Anti-seizure medications for Lennox–Gastaut syndrome. Cochrane Database Syst Rev 2021;4(4):CD003277. DOI:10.1002/14651858.CD003277.pub4; Cheng-Hakimian A., Anderson G.D., Miller J.W. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006;60(11):1497–501. DOI:10.1111/j.1742-1241.2006.01173.x; Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat 2011;7:399–407. DOI:10.2147/NDT.S13910; Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: Literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90. DOI:10.1016/j.ejpn.2014.05.008; Coppola G., Grosso S., Franzoni E. et al. Rufinamide in children and adults with Lennox–Gastaut syndrome: First Italian multicenter experience. Seizure 2010;19(9):587–91. DOI 10.1016/j.seizure.2010.09.008; Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70(21):1950–8. DOI:10.1212/01.wnl.0000303813.95800.0d; Inovelon® (rufinamide). Summary of Product Characteristics. Eisai Ltd. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000660/WC500032937.pdfTest.; Jaraba S., Santamarina E., Miró J. et al. Rufinamide in children and adults in routine clinical practice. Acta Neurol Scand 2017;135(1):122–8. DOI:10.1111/ane.12572; Joseph J.R., Schultz R.J., Wilfong A.A. Rufinamide for refractory epilepsy in a pediatric and young adult population. Epilepsy Res 2011;93(1):87v9. DOI:10.1016/j.eplepsyres.2010.10.017; Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res 2012;2(2):33–7. DOI:10.14581/jer.12009; Kim S.H., Lee J.H., Ryu H.W. et al. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy. Epileptic Disord 2013;15(1):49–54. DOI:10.1684/epd.2013.0557; Kluger G., Haberlandt E., Kurlemann G. et al. First European longterm experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010;17(4):546–8. DOI:10.1016/j.yebeh.2010.01.005; Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: A long-term, open-label extension study. Acta Neurol Scand 2010;122(3):202–8. DOI:10.1111/j.1600-0404.2010.01334.x; Kluger G., Bauer B. Role of rufinamide in the management of Lennox–Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007;3(1):3–11.; Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with Lennox–Gastaut syndrome: A single center study in Korea. Clin Neurol Neurosurg 2013;115(7):926–9. DOI:10.1016/j.clineuro.2012.09.021; McMurray R., Striano P. Treatment of adults with Lennox–Gastaut syndrome: Further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther 2016;5(1):35–43. DOI:10.1007/s40120-016-0041-9; Moavero R., Santarone M.E., Galasso C., Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev 2017;39(6):464–9. DOI:10.1016/j.braindev.2017.01.006; Montouris G., Aboumatar S., Burdette D. et al. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox–Gastaut syndrome in adult patients. Epilepsy Behav 2020;110:107146. DOI:10.1016/j.yebeh.2020.107146; Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox–Gastaut syndrome. Epilepsia 2014;55(Suppl 4):10–20. DOI:10.1111/epi.12732; Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8. DOI:10.1111/j.1528-1167.2012.03579.x; Mukhin K.Yu. Lennox–Gastaut syndrome. In: Epileptic Encephalopathies. John Libbey, 2014. Pp. 127–158.; Nikanorova M., Brandt C., Auvin S., McMurray R. Real-world data on rufinamide treatment in patients with Lennox–Gastaut syndrome: Results from a European noninterventional registry study. Epilepsy Behav 2017;76:63–70. DOI:10.1016/j.yebeh.2017.08.026; Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Epilepsy Res 2016;121:1–7. DOI:10.1016/j.eplepsyres.2016.01.002; Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan. Epilepsy Res 2014;108(9):1627–36. DOI:10.1016/j.eplepsyres.2014.08.019; Resnick T., Arzimanoglou A., Brown L.W. et al. Rufinamide from clinical trials to clinical practice in the United States and Europe. Epileptic Disord 2011;13(Suppl 1):S27–43. DOI:10.1684/epd.2011.0421; Samanta D. Management of Lennox–Gastaut syndrome beyond childhood: A comprehensive review. Epilepsy Behav 2021;114(Pt A): 107612. DOI:10.1016/j.yebeh.2020.107612; Sankar R., Chez M., Pina-Garza J.E. et al. Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox– Gastaut syndrome: Narrative review and expert opinion. Seizure 2023;110:42–57. DOI:10.1016/j.seizure.2023.05.018; Schimpf R., Veltmann C., Papavassiliu T. et al. Drug-induced QTinterval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm 2012;9(5):776–81. DOI:10.1016/j.hrthm.2012.01.006; Sharawat I.K., Panda P.K., Panda P., Dawman L. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox–Gastaut syndrome: A systematic review and meta-analysis. Seizure 2021;91:296–307. DOI:10.1016/j.seizure.2021.07.004; Strzelczyk A., Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs 2022;36(10):1079–111. DOI:10.1007/s40263-022-00955-9; Vendrame M., Loddenkemper T., Gooty V.D. et al. Experience with rufinamide in a pediatric population: A single center's experience. Pediatr Neurol 2010;43(3):155–8. DOI:10.1016/j.pediatrneurol.2010.04.003; Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9(4):353–412. DOI:10.1684/epd.2007.0144; Wheless J.W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies. J Child Neurol 2009;24(12):1520–5. DOI:10.1177/0883073809350508; Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox–Gastaut syndrome: A comprehensive overview. Paediatric Drugs 2011;13(2):97–106. DOI:10.2165/11586920-000000000-00000; https://rjdn.abvpress.ru/jour/article/view/448Test

الإتاحة: https://doi.org/10.17650/2073-8803-2023-18-4-8-25Test
https://doi.org/10.17749/2077-8333/epi.par.con.2022.124Test
https://doi.org/10.17650/2073-8803-2015-10-4-47-54Test
https://doi.org/10.17650/2073-8803-2018-13-2-7-19Test
https://doi.org/10.17650/2073-8803-2018-13-2-20-33Test
https://doi.org/10.1684/epd.2016.0817Test
https://doi.org/10.1002/14651858.CD003277.pub4Test
https://doi.org/10.1111/j.1742-1241.2006.01173.xTest
https://doi.org/10.2147/NDT.S13910Test
https://doi.org/10.1016/j.ejpn.2014.05.008Test

المؤلفون: E. D. Belousova, S. G. Burd, N. A. Ermolenko, K. Yu. Mukhin

المصدر: Эпилепсия и пароксизмальные состояния, Vol 14, Iss 3, Pp 276-293 (2022)

مصطلحات موضوعية: lennox–gastaut syndrome, diagnostic criteria, age evolution, diagnostic algorithm, treatment, rufinamide, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://www.epilepsia.su/jour/article/view/823Test; https://doaj.org/toc/2077-8333Test; https://doaj.org/toc/2311-4088Test

الوصول الحر: https://doaj.org/article/68234c94d0dd4b56a2ae4b7ee7c0b5d2Test

المؤلفون: Naveen, Paladugu Venkata¹, Ganapaty, Seru

المصدر: Research Journal of Pharmacy and Technology 14(9):4825-4831. 2021

المؤلفون: Sara Meirinho, Márcio Rodrigues, Ana Fortuna, Amílcar Falcão, Gilberto Alves

المصدر: Journal of Pharmaceutical Analysis, Vol 11, Iss 4, Pp 405-421 (2021)

مصطلحات موضوعية: Bioanalysis, Liquid chromatography, Perampanel, Retigabine, Rufinamide, Stiripentol, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2095177920310807Test; https://doaj.org/toc/2095-1779Test

الوصول الحر: https://doaj.org/article/005c87bf5151474baf6f7ff59838815fTest

المؤلفون: Avantika Dalvi, Punna Rao Ravi, Chandra Teja Uppuluri

المصدر: Frontiers in Pharmacology, Vol 13 (2022)

مصطلحات موضوعية: rufinamide, nanocrystals, thermoresponsive gel, nose-to-brain delivery, pharmacokinetics, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2022.943772/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/dd4ba098f2494e3ba2702ba5222377c9Test

المؤلفون: Bhattacherjee, D., Kovalev, I. S., Kopchuk, D. S., Rahman, M., Santra, S., Zyryanov, G. V., Das, P., Purohit, R., Rusinov, V. L., Chupakhin, O. N.

المصدر: Molecules

مصطلحات موضوعية: 1,2,3-TRIAZOLE, CLICK CHEMISTRY, CYCLOADDITION REACTION, MECHANOCHEMICAL SYNTHESIS, RUFINAMIDE SYNTHESIS, SOLVENT-FREE, ALKYNES, AZIDES, CATALYSIS, COPPER, TRIAZOLES, ALKYNE, AZIDE, RUFINAMIDE, TRIAZOLE DERIVATIVE, CHEMISTRY

وصف الملف: application/pdf

العلاقة: Bhattacherjee, D, Kovalev, IS, Kopchuk, DS, Rahman, M, Santra, S, Zyryanov, GV, Das, P, Purohit, R, Rusinov, VL & Chupakhin, ON 2022, 'Mechanochemical Approach towards Multi-Functionalized 1,2,3-Triazoles and Anti-Seizure Drug Rufinamide Analogs Using Copper Beads', Molecules, Том. 27, № 22, 7784. https://doi.org/10.3390/molecules27227784Test; Bhattacherjee, D., Kovalev, I. S., Kopchuk, D. S., Rahman, M., Santra, S., Zyryanov, G. V., Das, P., Purohit, R., Rusinov, V. L., & Chupakhin, O. N. (2022). Mechanochemical Approach towards Multi-Functionalized 1,2,3-Triazoles and Anti-Seizure Drug Rufinamide Analogs Using Copper Beads. Molecules, 27(22), [7784]. https://doi.org/10.3390/molecules27227784Test; Final; All Open Access; Gold Open Access; Green Open Access; https://www.mdpi.com/1420-3049/27/22/7784/pdf?version=1668494028Test; http://elar.urfu.ru/handle/10995/131327Test; 85142641257; 000887403000001

الإتاحة: https://doi.org/10.3390/molecules27227784Test
http://elar.urfu.ru/handle/10995/131327Test
https://www.mdpi.com/1420-3049/27/22/7784/pdf?version=1668494028Test

المؤلفون: Ming-Chi Lai, Sheng-Nan Wu, Chin-Wei Huang

المصدر: International Journal of Molecular Sciences, Vol 23, Iss 22, p 13677 (2022)

مصطلحات موضوعية: rufinamide (1-((2,6-difluorophenyl)methyl)-1H-1,2,3-triazole-4carboxamide), antiepileptic drug, Ca2+-activated K+ current, large-conductance Ca2+-activated K+ channel, hysteresis, voltage-gated Na+ current, Biology (General), QH301-705.5, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1422-0067/23/22/13677Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test

الوصول الحر: https://doaj.org/article/d3c4449be44444788c45d872cfc09647Test

المؤلفون: Dhananjay Bhattacherjee, Igor S. Kovalev, Dmitry S. Kopchuk, Matiur Rahman, Sougata Santra, Grigory V. Zyryanov, Pralay Das, Rituraj Purohit, Vladimir L. Rusinov, Oleg N. Chupakhin

المصدر: Molecules, Vol 27, Iss 22, p 7784 (2022)

مصطلحات موضوعية: click chemistry, mechanochemical synthesis, 1,2,3-triazole, cycloaddition reaction, Rufinamide synthesis, solvent-free, Organic chemistry, QD241-441

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1420-3049/27/22/7784Test; https://doaj.org/toc/1420-3049Test

الوصول الحر: https://doaj.org/article/5fc3bc5bbaf54acca1479611e710c905Test

المؤلفون: Sadaka, Peter M

المصدر: Undergraduate Student Research Internships Conference

مصطلحات موضوعية: Crystallization, Polymorphism, Morphology, Pharmacology, Rufinamide, PXRD, Biochemical and Biomolecular Engineering, Process Control and Systems

وصف الملف: application/vnd.openxmlformats-officedocument.presentationml.presentation

العلاقة: https://ir.lib.uwo.ca/usri/usri2022/ReOS/237Test; https://ir.lib.uwo.ca/context/usri/article/1322/type/native/viewcontent/Sadaka_Peter.pptxTest

الإتاحة: https://ir.lib.uwo.ca/usri/usri2022/ReOS/237Test
https://ir.lib.uwo.ca/context/usri/article/1322/type/native/viewcontent/Sadaka_Peter.pptxTest

المؤلفون: Gayatri Kakad, Sandhya L. Borse, Atul R. Bendale, Laxmikant B. Borse, Vaishali D. Naphade, Anil G. Jadhav

المصدر: Asian Pacific Journal of Health Sciences; Vol. 9 No. 4 (2022): Vol 9 | Issue 4 (S1)| Special 2022; 208-213 ; 2349-0659 ; 2350-0964

مصطلحات موضوعية: Antiepileptic, Method development, RP-HPLC, Rufinamide, Validation

وصف الملف: application/pdf

العلاقة: https://apjhs.com/index.php/apjhs/article/view/2932/1573Test; https://apjhs.com/index.php/apjhs/article/view/2932Test

الإتاحة: https://doi.org/10.21276/apjhs.2022.9.4S1.38Test
https://apjhs.com/index.php/apjhs/article/view/2932Test